Addressing Climate Change

There are more than 5 trillion pieces of plastic floating in our oceans. The U.S. transportation sector leads all other sectors in greenhouse gas emissions. Diseases that thrive in hot weather are killing important staple crops. Our reliance on products derived from fossil fuels is harming our planet.

Climate change is real but through biotechnology, we can meet these challenges head-on by making the same reliable plastics, foods, and fuels with less environmental impact.

Press Releases
January 20, 2022
Today, the Biotechnology Innovation Organization (BIO), in partnership with the Council of State Bioscience Associations (CSBA), released a new report on bioscience economic development best practices, “Driving the Bioscience Economy Forward During the COVID-19 Pandemic: Best Practices in State and…
January 13, 2022
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement in response to the Centers for Medicare and Medicaid Services’ (CMS) proposed National Coverage Determination (NCD) to restrict coverage for drugs used to treat…
November 19, 2021
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement after the House of Representatives passed the Build Back Better Act: “The legislation that passed the House today will upend a successful Medicare system and weaken…
Good Day BIO Newsletter
Subscribe to GoodDay BIO

Receive the best resource for the biotech industry with Good Day BIO, the only daily newsletter at the intersection of biotech, politics and policy. 

Letters, Comments & Testimony
January 12, 2021
The United States-Mexico-Canda Agreement has the potential to deliver tangible benefits for America's workers, farmers, and businesses by improving and strengthening the relationship between the United States and its two closest trading partners. However, that potential will not be realized without…
January 3, 2022
On Wednesday, December 29th, BIO submitted comments to the Food and Drug Administration’s recent draft guidance for industry entitled, Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the Federal Food, Drug, and Cosmetic Act. Existing regulations require each…
December 13, 2021
On Monday, December 13th, BIO submitted comments to the Food and Drug Administration’s recent draft guidance for industry entitled, Q13 Continuous Manufacturing of Drug Substances and Drug Products. The draft guidance was prepared under the auspices of the International Council for Harmonisation …